$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice and its incidence and prevalence continue to increase dramatically worldwide1. This arrhythmia affects up to 4% of the world population according to recent studies2. However, given that paroxysmal AF can be asymptomatic and may therefore escape detection, the true prevalence of AF is likely to be much higher than that presented in the literature.
The pathophysiology of AF has been intensely studied. Nevertheless, the underlying mechanisms of this complex arrhythmia remain incompletely elucidated and this reflects in the limited therapeutic options, with questionable efficacy. Animal studies have brought important insights into our understanding regarding AF pathophysiology and therapeutic management. Reentry, one of the main mechanisms involved in AF pathogenesis3, requires a certain mass of myocardial tissue in order to occur. Thus, large animals have generally been preferred in AF studies, whereas, due to the small size of their atria, rodents have long been considered 'resistant' to AF. However, the use of large animals is hampered mostly by handling difficulties. Meanwhile, although spontaneous AF has been shown to occur in rats4, long-term follow-up (up to 50 weeks) is required for the arrhythmia to occur in those models5. Models that ensure rapid AF occurrence in small rodents have also been developed. Most often, those models use acute electrical stimulation, often in the presence of other favoring conditions, such as concomitant parasympathetic stimulation or asphyxia, to artificially induce AF6,7. Although efficient, such models do not allow the evaluation of critical AF-related features, such as the progressive electrical, structural, autonomic, or molecular remodeling of the atria, nor the effects of conventional or non-conventional antiarrhythmic drugs on the atrial substrate or on the risk of ventricular pro-arrhythmia8,9.
The present work describes an experimental protocol of long-term transesophageal atrial burst pacing for rapid and efficient induction of AF in rats. The protocol is suitable for both acute and long-term studies and can be successfully used in rats with healthy or remodeled hearts, in the presence of a wide variety of risk factors, allowing the study of AF pathophysiology, identification of novel therapeutic targets, and evaluation of novel prophylactic and/or therapeutic strategies.